From June 27 to 28, Xu Jianping, director of the National Development and Reform Commission (NDRC), went to Lianyungang City, Jiangsu Province, to investigate the development of China-Europe (Asia) liner. During the visit, Xu Jianping came to Chiatai Tianqing Pharmaceuticals to investigate the enterprise's practice of international cooperation and innovation under the promotion of the "Belt and Road" initiative. Vice President of Chiatai Tianqing, Mr. Chen Hui and Mr. Xia Chunguang accompanied him.

Xu Jianping and his entourage visited the production workshop of Chiatai Tianqing and learned about the development of the enterprise in detail. Xu Jianping affirmed the achievements made by Chiatai Tianqing in enterprise operation, R&D innovation and internationalization, and encouraged the enterprise to continue to plough into scientific and technological innovation, accelerate the development of new quality productivity of pharmaceuticals, and promote the development of the enterprise to a new level. He emphasized that the enterprise should have firm confidence in international development, combine international cooperation with international market development, take the initiative to participate in the construction of "One Belt, One Road", and explore the opportunities of international cooperation along the route. We will take the initiative to participate in the construction of "Belt and Road", explore the opportunities of international cooperation along the route, allocate resources and open up the market in a wider scope, and gather the power of cooperation and development, so as to realize higher quality development with higher level of internationalization.

Chen Hui introduced the latest scientific research progress and internationalization layout of the enterprise. He said that under the promotion of "comprehensive innovation" strategy, Chiatai Tianqing's R&D investment has been increased to 17% of sales revenue, and introduced, cultivated, and created a team of innovative talents with reasonable structure and excellent quality to promote innovation and R&D to make qualitative breakthroughs. Since this year, the company has successively listed three Class 1 innovative drugs, namely Anektinib, Behmosubaisumab and Efinavir, and there are also a number of innovative drugs under research. He pointed out that under the guidance of the "Belt and Road" initiative, the company has made certain progress in the introduction of international innovation platforms and pipelines, as well as overseas clinical and international sales. In the future, the company will firmly lay out its internationalization strategy, and through "innovation and internationalization", develop and innovate globally, strive to become the best Chinese partner of multinational pharmaceutical companies, and promote global innovative drugs to better and faster benefit Chinese patients.

https://mp.weixin.qq.com/s?__biz=MzA5NDE4ODc2MA==&mid=2650367685&idx=1&sn=bac05353df070bc7b3259292d20e1f59&chksm=885fa372bf282a64a7fd7426f912216c8cb4b2bfac41e1c0fb78738cc3415e631a6a66b3d1f6&mpshare=1&scene=1&srcid=0701SY5gB7TjtHGMqtAXj8kR&sharer_shareinfo=9398e3b3e581dbe484a5a6a248de5c0e&sharer_shareinfo_first=9398e3b3e581dbe484a5a6a248de5c0e#rd